Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002258
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Phase I Open Label Trial to Evaluate the Safety Tolerance and Biological Effects of SDZ ILE-964 Recombinant Human Interleukin-3 RhIL-3 in HIV Infected Patients With Cytopenia
Sponsor:
Sandoz
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase I Open Label Trial to Evaluate the Safety Tolerance and Biological Effects of SDZ ILE-964 Recombinant Human Interleukin-3 RhIL-3 in HIV Infected Patients With Cytopenia
Status:
COMPLETED
Status Verified Date:
1992-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the safety tolerability and maximum tolerated dose of SDZ ILE 964 administered by daily subcutaneous injections in patients infected with human immunodeficiency virus HIV who have cytopenias low blood cell counts To obtain information about the biologic effects of SDZ ILE 964 administration in improving blood counts in HIV-infected patients To obtain information about the effects of SDZ ILE-964 administration on both parameters of HIV replication and on residual immunologic function
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B104 | None | None | None |